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Abstract
The effectiveness of angiotensin-converting enzyme inhibitors (ACEIs) and 
angiotensin II receptor blocker AT-1 (ARBs) in reducing the systemic hypertension 
(SH) is widely known. However their comparative outcomes resulting from pro-
longed use remain unknown. The objective of this chapter is to discuss the evidence 
of prospective randomized double-blind clinical trials; all the events result from 
prolonged use of ACEIs or ARBs in hypertensive patients. In lowering blood pres-
sure, the use of ACE inhibitors or ARBs reduces, in long-term use, the risk of acute 
myocardial infarction, stroke, and heart failure. However, the use of ACEIs is effec-
tive in an overall quantitative analysis; the total mortality regarding cardiovascular 
causes an outcome that was not observed with the use of ARBs. This fact is assumed 
to be related to the higher plasma concentration of bradykinin in the use of ACEIs, a 
well-known cardiovascular-protective factor.
Keywords: hypertension, outcomes, ACEI, ARB, angiotensin-converting enzyme 
inhibitor, angiotensin II receptor blocker
1. Introduction
Hypertension is a manifestation in which there is an elevation of blood pressure 
levels to the point of causing imbalance in homeostasis and, consequently, leading 
the organism to a debilitated and pathological state with clinical repercussions [1]. 
Also, systemic arterial hypertension (SAH) is defined as “a multifactorial clinical 
condition characterized by elevated and sustained levels of blood pressure” [2, 3], 
considered when it is observed that a value >140 mmHg for systolic blood pressure 
and/or >90 mmHg for diastolic blood pressure [4].
SAH presents itself as one of the main risk factors for cardiovascular diseases 
[5], and in a recent study, it was shown as the risk factor with the highest number 
of citations in studies [6]; its incidence is increasing annually, reaching values of 
population of approximately 20% of Brazilians [7] or 24.3% [8]. Therefore, the 
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control and prevention of SAH are fundamental to improve the quality of life and 
health indicators of the population.
The treatment of this clinical condition is based on three primordial objectives: 
the decrease in blood pressure levels; the maintenance of the desired levels, in 
view of the singular conditions of each patient; and adherence of the patient to the 
treatment as well as its continuity. From these perspectives, the measures in order to 
achieve this triad are based on two therapeutic pathways: changes in lifestyle and/
or the use of drugs. Regarding changes in lifestyle, which also show efficacy in the 
prevention of hypertensive status, the most important are [9, 10] regular practice 
of physical activities, abstinence from alcohol, changes in food style prioritizing the 
decrease in salt intake and the increase in the consumption of fruit and vegetables, 
cessation of smoking, weight loss, control of psychosocial stress, slow breathing, 
monitoring, and surveillance by a multidisciplinary team.
Regarding the use of drug therapies, and according to their current availability, 
there are the following classes of medications [9]: diuretics, adrenergic inhibitors 
(central alpha-2 agonists, beta-blockers, and alpha-blockers), calcium channel 
blockers, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II recep-
tor blockers AT1 (ARBs), and direct vasodilators such as nitrates.
Because they act primarily in one of the most important systems for the devel-
opment of SAH, the renin-angiotensin-aldosterone system (SRAA) [11], four 
classes of medications stand out and are effective options in reducing morbidity 
and mortality due to cardiovascular diseases [12], direct renin inhibitors, ACEIs, 
ARBs, and aldosterone antagonists. Among these classes, the ACEIs and the ARBs 
are among the most prescribed options worldwide [11]. Therefore, the study and 
detailed knowledge of both classes is of fundamental importance.
The control of SAH is performed by the ACEI by blocking the transformation of 
angiotensin I in angiotensin II in the blood and tissues, while the ARB antagonizes 
the action of angiotensin II by means of the specific blockade of their AT1 receptors. 
In addition, studies show that the use of these antihypertensive patients is closely 
related to the decrease in the progression of renal diseases and in the prevention of 
heart and/or vascular diseases, such as acute myocardial infarction and stroke [13].
On the other hand, in addition to the aforementioned actions, drugs can act in 
other places and systems, also causing adverse and deleterious events in the organ-
ism. These include dry cough, taste alteration, dizziness, hypersensitivity reactions 
with rash (rash), angioneurotic edema, hyperkalemia, reduction of glomerular 
filtration with increased serum levels of urea and creatinine, and fetal complica-
tions [11]. Thus, countless events are reported from the use of these drugs, whether 
they are beneficial or malevolent.
2. ACEI and ARB in the management of hypertension
Assuming that the SRAA is a fundamental regulator of cardiovascular and renal 
functions, ACEI and ARB have different outcomes in the regulatory systems of the 
human organism, especially in the cardiovascular system. In recent decades, several 
clinical studies have confirmed that SRAA suppression reduces cardiovascular 
mortality and total mortality of patients [14].
Despite this, the protective role of SRAA inhibitors in relation to cardiovascular 
mortality was questioned by studies such as non-insulin-dependent diabetes, hyper-
tension, microalbuminuria or proteinuria, cardiovascular events, and ramipril study 
(DIABHYCAR) [15] which showed that the use of ACE inhibitors had no effect on 
cardiovascular mortality in patients with type 2 diabetes mellitus type 2 (DM2) 
and albuminuria. Also, studies such as Randomized Olmesartan and Diabetes 
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Microalbuminuria Prevention (ROADMAP) study [16] ended up demonstrating a 
high rate of cardiovascular mortality in patients using Olmesartan and DM2.
In this chapter, we seek to synthesize the main prospective, randomized and 
double-blind clinical trials that report the outcomes resulting from the use of renin-
angiotensin system inhibitors in hypertensive patients, and to extend the discussion 
previously made in an article published by the author [17].
The following outcomes will be analyzed: total mortality (including cardiovas-
cular and other causes of death in this specific population), cardiovascular mortal-
ity, acute myocardial infarction, stroke, heart failure, and hospitalization due to 
heart failure, and an addition of all these outcomes (total outcomes).
3. ACEI × ARB: the state of the art in terms of medical evidence
The use of ACEI or ARB has always been part of the first line of treatment of 
patients with systemic arterial hypertension, especially in the newly diagnosed or 
long-term patients. Not uncommon are the revaluation of each medication, due to 
the inefficacy in reducing pressure values or in the presence of side effects (cough-
ing is a very common effect of ACE inhibitors, leading to the main cause of treat-
ment change) [9].
Thus, even with the notion that the ACEI and the ARB are equally effective in 
reducing pressure in patients with systemic arterial hypertension, their efficiencies 
compared and their advantages, disadvantages, and outcomes, related to recent or 
chronic use, remain unknown or liable to be questioned [11].
Related to the last major clinical trials, such as SOLVD (enalapril in heart 
failure), HOPE (ramipril in patients with high CVD risk), and EUROPA (perindo-
pril in stable coronary disease) studies, we noticed that the inhibition of the SRAA 
in specific populations caused a significant reduction in outcomes such as general 
mortality, mortality from cardiovascular causes, acute myocardial infarction, and 
STROKE [14].
Even so, the large number of studies performed, comparing the use of ACEI or 
ARB in reducing outcomes in their patients, was not organized and correlated in a 
review format with well-established characteristics. Thus, it is perceived that the 
latest systematic reviews with meta-analyses and clinical trials, related to the topic, 
can be framed in the following situations:
• Systematic reviews, with meta-analysis, based on clinical trials that studied 
the outcomes related to the use of ACE inhibitors or ARB without their study 
population necessarily composed of essential hypertensive patients [15, 16].
• Research that studied the use of ACEI in hypertensive patients secondary to 
other pathologies, although the focus of the study was the evaluation of the 
symptomatic treatment of the disease and not the hypertension itself [17].
• Studies that used as a control group another drug, which is not considered as 
the first line of treatment [18].
• Studies that analyzed hypertensive patients with control groups or with 
standard first-line treatment, according to the hypertension guidelines used by 
the research team [19, 20].
This presents itself as one of the most current and systematic revisions of the 
area. By analyzing 20 clinical trials, involving a number of 158,998 patients, the 
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authors were able to correlate the outcomes related to the analyzed studies, such as 
cardiovascular and total mortality. However, the present study did not stratify the 
influence of a given variable (e.g., which drug has a higher mortality rate per stroke 
of heart failure?), as well as its selected studies involved various types of control 
groups when compared to the use of ACEI or ARB [14]. Thus, there was an increase, 
in the last instance, of the individual heterogeneity of each patient according to 
their medication and particular health condition.
Another meta-analysis of Ho et al. [19] encompassed 10 clinical studies that 
used ACEI or ARB with its outcomes stratified in cardiovascular mortality, myocar-
dial infarction, stroke, and overall mortality. However, it involved studies in which 
the population was not hypertensive in some cases, such as the Comparison of 
Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis (CAMELOT) study, 
which did not present its series of outcomes due to the use of the drug but is in rela-
tion to deep vein thrombosis [21–23].
Thus, in view of these systematic reviews with meta-analyses, published in 
high-impact journals, it can be defined that all of them correlated the presence 
of outcomes, due to the use of ACEI or ARB, only in certain populations, for 
example, in patients with thrombosis or diabetics. Thus, only a general panorama 
is provided, despite the magnitude of the use of medications and their outcomes, 
in a population with essential hypertension. Thus, the relationship of a pathology, 
not necessarily related to hypertension, or the presence of a comorbid syndrome 
such as DM2 in hypertensive patients would present relationships with other 
complexes to safely affirm the direct effect of antihypertensive medication on 
outcomes.
However, as an attempt to increase the number of patients and studies involved 
in the final analysis, all used studies that presented some of the biases in the previ-
ously cited items, such as the extrapolation of hypertensive populations in groups 
Non-hypertensive majority, or the use of other therapies in the control group other 
than placebo.
4. ACEI × ARB correlation
Our analysis of the literature regarding the use of ACEI or ARB in the hyperten-
sive population selected 17 studies over the past 10 years, covering a total of 73,761 
patients [17].
Of these 17 articles, 12 studies were randomized for therapy with ARB 
(n = 24,697) compared to control (n = 24,722), while five compared the use of ACEI 
(n = 12,170) with the control group (n = 12,172) [24].
All patients in the studies were considered as prehypertensive or hypertensive 
according to the definition of each study, and the mean base pressure ranged from 
123 to 169 mmHg. The mean age of the patients ranged from 51 to 76.9 years, with 
the follow-up time of the studies ranging from 2.25 to 5.5 years.
4.1 Total mortality
A total of 15 studies (n = 70,983) reported events related to total mortality. Two 
studies [25, 26] were statistically significant in reducing mortality compared to the 
control group (OR = 0.831, 95% CI, [0.730–0.945], P = 0.005) and (OR = 0.563, 
95% CI, [0.341–0.931], P = 0.025), respectively. In addition, the results showed a 
significant total difference between ACEI and control group (OR = 0.851, 95% CI, 
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[0.776–0.935], P = 0.001). In relation to the ARB and control group, no significance 
was evidenced (OR = 1024, 95% CI, [0.960–1.091], P = 0.471) (Figure 1).
4.2 Cardiovascular mortality
The cardiovascular mortality was analyzed in 13 studies (n = 64,460). One 
study [27] showed a significant reduction in the cardiovascular mortality for ACEI 
compared to the control group (OR = 0.733, 95% CI, [0.625–0.860], P = 0.000).
As for the ARB, the opposite was observed in one study, with an increase in the 
risk in the event when comparing with the control group [28] (OR = 5.011, 95% CI, 
[1.449–17.334], P = 0.011).
Thus, the studies with ACEI showed a reduction in the cardiovascular mortality 
(OR = 0.775, 95% CI, [0.689–0.872], P = 0.000), while for the use of ARB there 
was no significant reduction compared to the control group (OR = 0.947, 95% CI, 
[0.849–1.056], P = 0.324) (Figure 2).
4.3 Acute myocardial infarction
Regarding the occurrence of AMI, two studies evaluating ACEI were beneficial 
for the reduction of the event (OR = 0.785, 95% CI, [0.689–0.895], P = 0.000), 
(OR = 0,769, 95% CI, [0.658–0.899], P = 0.001). Related to the therapy with ARB, 
only one study showed statistical significance to decrease AMI when compared to 
the control group (E-COST, 2005) (OR = 0.428, 95% CI, [0.202–0.905], P = 0,026). 
A total of 14 studies (n = 67,237) showed that both ACEI and ARB are positive in the 
reduction of such event when compared to the control group therapy, with greater 
significance for ACEI (OR = 0.784, 95% CI, [0.712–0.863], P = 0.000) on ARB 
(OR = 0.906, 95% CI, [0.834–0.985], P = 0.020) (Figure 3).
Figure 1. 




Of the 13 studies (n = 65,724) that evaluated stroke, 2 of them, 1 involving 
ACEI (OR = 0.681, 95% CI, [0.553–0.838], P = 0.000) and another involving ARB 
(OR = 0.587, 95% CI, [0.402–0.855], P = 0.005), showed statistical significance 
Figure 2. 
Forest plots summarizing the correlation of (A) ACEI and (B) ARB use for cardiovascular mortality.
Figure 3. 
Forest plots summarizing the correlation of (A) ACEI and (B) ARB use for acute myocardial infarction.
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for reduction of stroke when compared to the control group. Similar to the results 
for AMI, the reduction of stroke, compared to the control group, was significa-
tive in the two classes of medications, with a more expressive reduction for ACE 
(OR = 0.770, 95% CI, [0.654–0.908], P = 0.002) on BRA (OR = 0,890, 95% CI, 
[0.820–0.965], P = 0.005) (Figure 4).
Figure 4. 
Forests plots summarizing the correlation of (A) ACEI and (B) ARB use for stroke.
Figure 5. 




A total of 12 studies (n = 62,403) analyzed heart failure. Two comparing the 
use of ACEI with a control group caused a significant reduction of the outcome, 
(OR = 0.759, 95% CI, [0.663–0.869], P = 0.000] and (OR = 0.607, 95% CI, [0.443–
0.833], P = 0.002). The same was observed for three studies with ARB (OR = 0.718, 
95% CI, [0.617–0.836], P = 0.000), (OR = 0.672, 95% CI, [0.502–0.900], 
P = 0.008) and (OR = 0.451, 95% CI [0.278–0.734], P = 0.001). Thus, the two 
therapies analyzed were significant in the reduction of the event, with proximity 
of both classes in relation to the reduction of heart failure compared to the control 
group: ACEI (OR = 0,762, 95% CI, [0.677–0.857], P = 0.000) and BRA (OR = 0,799, 
95% CI, [0.724–0.882], P = 0.000) (Figure 5).
4.6 Total outcomes
Analyzing all the outcomes described, the 17 studies (n = 73,761) showed that 
both the uses of ACEI (OR = 0.890, 95% CI, [0.837–0.945], P = 0.000) and of ARB 
(OR = 0.916, 95% CI, [0.877–0.956], P = 0.000) are favorable to a significant reduc-
tion in the occurrence of mortality events (Figure 6).
5. Discussion
The blockade of the renin-angiotensin-aldosterone system, regardless of the 
level in which it is performed, by itself, is a demonstrably relevant factor in lowering 
blood pressure. Both the inhibition of angiotensin-converting enzyme (ACEI) and 
the blockade of the AT-1 receptor of angiotensin II (ARB) provide a decrease in the 
Figure 6. 
Forests plots summarizing the correlation of (A) ACEI and (B) ARB use for all the outcomes.
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smooth muscle contraction in the arterial endothelium and thus lead to a reduction 
in the pressure values in both drug regimens [5].
With this basis, associated with the data presented in the results, it was already 
expected that, when comparing the use of ACEI or ARB with the control group, 
there was a decrease in the development of myocardial infarction, stroke, and heart 
failure (in favor of the first group [ACEI or ARB]). The decrease in blood pressure 
constitutes an agent that directly causes an improvement in the circulatory system 
and in the perfusion system, and, as a consequence, there is a decrease in vascular 
pathologies, especially in the present study, for these outcomes. Thus, the first plau-
sible analysis of conclusion is that both the uses of ACEI and the ARB are efficient 
in decreasing blood pressure values as well as in the decrease of the hard outcomes. 
Quantitatively, it is noteworthy that the values, in these three outcomes, are more 
relevant in favor of the use of ACEI, when compared with the use of ARB, as seen in 
the charts of Figures 4–6. Despite this numerical superiority, in medical practice, 
both medications are relevant and preventive in terms of the three outcomes and 
therefore have their use indicated.
However, despite the synergistic effects of these medications in the hypertensive 
condition, their association is contraindicated. This contraindication is based on 
the fact that its association, when compared with its isolated use, does not cause 
improvement of cardiovascular outcomes, although there is an additional reduc-
tion in blood pressure [25]. In addition, the concomitant use of both medications 
presents, based on concrete evidence, an increase of at least 10% in the relative risk 
of cancer [26].
However, when analyzing the total mortality and cardiovascular mortality, there 
were differences. For these outcomes, as shown in Figures 2 and 3, the use of ACEI 
proved to be significant in relation to the statistic, while the use of ARB showed no 
differences compared to the control group. This fact, regarding the total mortal-
ity, corroborates with the data presented by van Vark [16] where there was a 10% 
decrease in mortality due to all causes, over 4 years, with the use of ACEI, while the 
use of ARB does not rush any impact. However, related to the cardiovascular mor-
tality, this same review did not present differences between the two drugs, whereas, 
in our review, the differences were statistically significant [14].
Given this, a reduction in the values of overall and cardiovascular mortalities 
with the use of ACEI, and in view of the follow-up time of the studies allocated 
here (from 27 to 66 months), we relate this difference observed to an increase or 
decrease in the serum concentration of some endogenous molecular factor, i.e., 
produced by the angiotensin-renin system itself.
Based on the physiological analysis of the blockade of ACEI and ARB drugs 
in the angiotensin-aldosterone cascade, we found that the role of ACE inhibitors 
occurs by inhibiting the conversion of angiotensin I into angiotensin II, while the 
ARB acts later in this process, blocking the receptor of the molecule of angiotensin 
II. Thus, there is a decrease in the serum values of angiotensin II in the use of ACEI, 
which does not occur with the use of ARB [27].
Based on this mechanism of action, the use of ACEI ultimately provides higher 
levels of polypeptide hormones, being the most physiological importance in this 
context, the bradykinin [28].
Bradykinin is an inflammatory polypeptide, which is responsible for the mainte-
nance of the inflammation cascade as well as for providing vasodilation, a necessary 
step so that the molecular and cellular agents of the inflammatory cascade can act 
on the site of possible injury. Its inactivation is performed mainly by carboxypep-
tidase II (kininase type II) of the lung parenchyma. Coincidentally, the kininase II, 
which inactivates bradykinin, is the same inhibited by the ACEI. Therefore, these 
medications, in addition to decreasing the concentration of angiotensin II, a potent 
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vasoconstrictor, collaborate to increase the pool of bradykinin, a physiological 
inflammatory vasodilator. Thus, there is an even greater increase in the hypotensive 
effects as well as a greater synergism regarding the reduction of other outcomes 
from vasoconstriction, caused by hypertensive conditions [29–31].
Thus, the benefits of using ACE inhibitors, resulting from the increase in 
the amount of bradykinin in the body, seem to have an additional benefit in the 
population with essential hypertension. This fact stems from the knowledge, about 
80 years ago, of the modulating roles of bradykinins in the renin-angiotensin sys-
tem, not only in the mechanism of vasodilation but also in the ventricular remodel-
ing in patients with hypertension [32, 33].
As for the other outcomes such as infarction, stroke, and heart failure, the 
increase in circulating bradykinin in these patients, due to its already explained 
vasodilating properties, also has a positive effect. Among these effects, we highlight 
the performance in the maintenance of the coronary reserve as well as in the conse-
quent prevention of infarction [34]. In addition, bradykinin was also identified as 
an endogenous factor that, associated with other molecules, favors the maintenance 
of myocardial perfusion and consequently promotes the prevention of ventricular 
remodeling in heart failure [34].
Related to the prevention of stroke, as was verified in the quantitative difference 
between these outcomes when compared to the population using ACEI, the increase 
in bradykinin implies the increase of the cerebral arterial flow [35, 36].
However, although we observe that the use of ACEI is intimately related to 
the decrease in infarction, stroke, and heart failure, these effects do not present a 
significant difference when compared to the use of ARB (Figures 3–5).
This characteristic is due to the fact that, even if the ACEIs have a significant 
increase in the concentration of bradykinins, its use is also implicated in the 
increase of other molecular factors which, in turn, present a myriad of receptors 
with often antagonistic functions. This may facilitate, hinder, or even have no effect 
on the action of the bradykinin in those outcomes but rather present more complex 
interactions in the function of these pathologies [37–39].
Some of these substances have already been discovered, such as prostaglandins 
and prostacyclins. However, the cellular molecule-receptor interaction and the best 
detailing of its cardiovascular-protective properties still lack studies to discover its 
relations with bradykinin and, above all, the relationship between the use of ACEI 
and the hypertensive condition in infarction, stroke, and heart failure. Thus, so far, 
it is only possible to infer the main role of bradykinin and a possible nonspecific 
interference of these factors in such pathologies [40–42].
Now, related to total and cardiovascular mortalities, we believe that the reduc-
tion of these outcomes observed in the use of ACEI may be closely related to the 
increase in the bloodstream of bradykinin. This fact is justified in view of the 
benefits that bradykinin promotes, in the long term, in the maintenance of vascu-
lar integrity. This molecule has a positive impact on the prevention of microvas-
cular alterations, which occur in certain diseases, in this case hypertension. This 
prevention tends to take place because bradykinin, via B2 receptors, protects the 
viability of the endothelium exposed to necrosis and apoptotic in hostile environ-
ments [43]. These situations are not observed when using the ARB. This is because 
its mechanism of action does not involve a pathway that changes the concentra-
tion of other mediators of blood pressure regulation, in addition to angiotensin 
II. Therefore, the use of ACEI is more effective than the use of ARB in these 
long-term outcomes.
As a consequence of this difference in the outcomes, total mortality and cardio-
vascular mortality, a decrease in the total outcomes with the use of ACEI was also 
predicted, as shown in Figure 6.
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Moreover, analyzing the consumption of ACEI and ARB, it is observed that in 
recent years the consumption of ACEI decreased, while the ARB showed significant 
growth. In the face of the literature and the present study, it can be corroborating 
that this situation does not present a relevant scientific basis [44].
6. Limitations of the ACEI × ARB analysis
The main limitation of this review involves the variation between the population 
samples, such as the different doses of the medications and the control group, and 
the studies with different follow-up times. In addition, some studies called therapy 
as a placebo without exactly specifying this information.
Also, for medical and ethical reasons, the vast majority of studies made it clear 
that both groups in use of ACEI and in use of placebo were already using other 
antihypertensive drugs. Thus, it cannot be inferred whether these medications in 
use could influence the information presented here.
It is also noteworthy that the study was based on analyzing the outcomes of 
different classes, ACEI and ARB. Thus, it should be considered that differences 
between the various drugs of each class are possible.
7. Conclusion
Through the use of ACEI and ARB, the pressure levels present significant 
reductions with both medications. Also, in the long term, the two therapies provide 
a decrease in the risk of hard outcomes such as acute myocardial infarction, stroke, 
and heart failure. However, the use of ACEI is effective in the reduction of the 
overall and cardiovascular-related mortality, facts not seen using the ARB. Thus, it 
is assumed that this reduction is due to the higher concentration of bradykinin, in 
the use of ACEI, due to its cardiovascular-protective properties, and not linked to 
the pressure drop only.
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